Sugi Predict

Sugi Predict / Compounds / SCHEMBL468798

SCHEMBL468798

SCHEMBL468798

CC(=O)N[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 1/20 0.50
▸ USP2 O75604 1/20 0.47
▸ SLCO1B1 Q9Y6L6 1/20 0.47
▸ LMNA P02545 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ PTGS2 P35354 1/20 0.38
▸ THPO P40225 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ TGFBR1 P36897 2/20 0.35
▸ OR51E2 Q9H255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27182003 1.00 PDE4A (0.50) PDE4AUSP2SLCO1B1LMNAL3MBTL1
SCHEMBL11225324 1.00 PDE4A (0.50) PDE4AUSP2SLCO1B1LMNAL3MBTL1
SCHEMBL468705 1.00 PDE4A (0.50) PDE4AUSP2SLCO1B1LMNAL3MBTL1
SCHEMBL468790 1.00 PDE4A (0.50) PDE4AUSP2SLCO1B1LMNAL3MBTL1
Acetic Acid SCHEMBL5160517 0.98 PDE4A (0.48) PDE4AUSP2SLCO1B1LMNAL3MBTL1
SCHEMBL9235255 0.86 LMNA (0.44) PDE4AUSP2SLCO1B1LMNAL3MBTL1
SCHEMBL8804538 0.84 PDE4A (0.41) PDE4AUSP2SLCO1B1LMNAL3MBTL1
SCHEMBL2729688 0.83 USP2 (0.41) PDE4AUSP2SLCO1B1LMNAL3MBTL1
SCHEMBL8077206 0.83 LMNA (0.41) PDE4AUSP2SLCO1B1LMNAL3MBTL1
SCHEMBL8072512 0.83 LMNA (0.41) PDE4AUSP2SLCO1B1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020068665-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2020-04-02 — — WO claimed
US-RE44302-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-06-18 — — US claimed
US-RE44017-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use YU RUEY J (US) 2013-02-19 — — US claimed
US-RE42902-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use TRISTRATA, INC. (US) 2011-11-08 — — US claimed
US-RE41339-E1 N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use TRISTRATA, INC. (US) 2010-05-18 — — US claimed
US-RE41278-E1 N-acetyl aldosamines and related N-acetyl compounds, and their topical use TRISTRATA, INC. 2010-04-27 — — US claimed
EP-1639994-A2 Topical composition comprising N-acetylaldosamines or N-acetylamino acids Yu, Ruey J., Dr. (US) 2006-03-29 — — EP claimed
EP-1570840-A2 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2005-09-07 — — EP claimed
US-20050171194-A1 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions YU RUEY J (US) 2005-08-04 — — US claimed
WO-2005055947-A2 ENLARGEMENT OF MUCOCUTANEOUS OR CUTANEOUS ORGANS AND SITES WITH TOPICAL COMPOSITIONS YU RUEY J (US) 2005-06-23 — — WO claimed
US-6524593-B1 Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails TRISTRATA, INC. 2003-02-25 — — US claimed
EP-1143925-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS Yu, Ruey J., Dr. (US) 2001-10-17 — — EP claimed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 — — US claimed
WO-2000040217-B1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-10-05 — — WO claimed
WO-2000040217-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-07-13 — — WO claimed
US-20210338558-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2021-11-04 — — US disclosed
EP-2311452-B2 Topical composition comprising n-acetyl glucosamine YU RUEY J (US) 2020-12-30 — — EP disclosed
WO-2000040217-A1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-07-13 — — WO disclosed
US-5037739-A Measuring reduced nicotinamide adenine dinculeotide formed NODA INSTITUTE FOR SCIENTIFIC RESEARCH (JP) 1991-08-06 — — US disclosed
US-4960701-A CULTURE PRODUCT FROM FLAVOBACTERIUM; CONVERTING SIALIC ACID TO LACTONE WHILE REDUCING NAD TO NADH NODA INSTITUTE FOR SCIENTIFIC RESEARCH (JP) 1990-10-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338558-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN COL14A1, COL2A1, COL1A1 PDE4A 2961/4885USP2 2681/4885SLCO1B1 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.